GlassScriptPhysician profile
Maya M Beplat
NPI 1043722655
$5,566.34
in general payments reported to CMS, 2019-2025
38 companies · $2,070 in 2025
The $2,070 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.76 · 2022: $426 · 2023: $1,551 · 2024: $1,482 · 2025: $2,070.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,411 · Consulting Fee: $500 · Education: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,411.22 |
| Consulting Fee | $500.00 |
| Education | $191.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $607.28 | 2022-2025 | Carvykti, Rybrevant, Erleada |
| Astrazeneca Pharmaceuticals LP | $604.10 | 2023-2024 | Imfinzi, Lynparza, Enhertu |
| Daiichi Sankyo INC. | $464.70 | 2022-2025 | Enhertu, Datroway |
| Novartis Pharmaceuticals Corporation | $455.79 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $439.81 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Puma Biotechnology, INC. | $393.90 | 2022-2025 | Nerlynx |
| Pfizer INC. | $289.31 | 2022-2025 | |
| Abbvie INC. | $238.84 | 2024-2025 | |
| Gilead Sciences, INC. | $223.01 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $177.91 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $151.46 | 2023-2025 | Tecentriq, Itovebi, Tecentriq Hybreza |
| Genentech, INC. | $145.53 | 2024 | Avastin, Phesgo, Tecentriq |
| Seagen INC. | $128.52 | 2021-2023 | Tivdak, Tukysa, Padcev |
| Tersera Therapeutics LLC | $120.26 | 2022-2025 | Zoladex, Xermelo |
| Stemline Therapeutics INC. | $117.29 | 2023-2025 | Orserdu |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maya Beplat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.